BMS-582949 + methotrexate

BMS-582949 + methotrexate is an investigational combination therapy for rheumatoid arthritis. BMS-582949 is a small molecule dual-action kinase inhibitor that targets p38 mitogen-activated protein kinase (p38 MAPK), inhibiting both its activation and functional activity. This pathway plays a key role in regulating inflammatory processes central to the pathogenesis of rheumatoid arthritis. Methotrexate is a well-established disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase, interfering with DNA synthesis and immune cell proliferation. The combination has been studied in patients with stable rheumatoid arthritis to assess safety, pharmacokinetics, and efficacy when administered together[1][3][4][7][10].